You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • SAT0142 Immunogenicity of the Novel Anti-Il-17A Antibody, Secukinumab, with Intravenous and Subcutaneous Dosing Regimens in Healthy Subjects and Patients

Citation Tools

Article menu
Download PDFPDF
Scientific Abstracts
Rheumatoid arthritis - other biologictreatment
SAT0142 Immunogenicity of the Novel Anti-Il-17A Antibody, Secukinumab, with Intravenous and Subcutaneous Dosing Regimens in Healthy Subjects and Patients

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Klein U, Liang E, Vogel B, et al
SAT0142 Immunogenicity of the Novel Anti-Il-17A Antibody, Secukinumab, with Intravenous and Subcutaneous Dosing Regimens in Healthy Subjects and Patients
Annals of the Rheumatic Diseases 2013;72:A630.